Alogliptin (Nesina) for adults with type-2 diabetes

P and T

Volumn 39, Issue 3, 2014, Pages 186-202

  Dineen, Laura ^a   Law, Connie ^a   Scher, Rebecca ^a   Pyon, Eunice ^a  

^a LONG ISLAND UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALOGLIPTIN; ALOGLIPTIN PLUS METFORMIN; ALOGLIPTIN PLUS PIOGLITAZONE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE; BILE ACID SEQUESTRANT; CANAGLIFLOZIN; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DIPEPTIDYL PEPTIDASE IV; DOPAMINE 2 RECEPTOR STIMULATING AGENT; GASTRIC INHIBITORY POLYPEPTIDE; GLIBENCLAMIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; HYPERGLYCEMIC AGENT; INSULIN; LINAGLIPTIN; MEGLITINIDE; METFORMIN; PIOGLITAZONE; PLACEBO; PROINSULIN; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; UNINDEXED DRUG; VILDAGLIPTIN;

ACUTE CORONARY SYNDROME; ADD ON THERAPY; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR DISEASE; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; HYPERSENSITIVITY; HYPOGLYCEMIA; INCIDENCE; INSULIN RESISTANCE; LIVER DYSFUNCTION; LIVER FAILURE; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RHINOPHARYNGITIS; SINGLE DRUG DOSE; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; UPPER RESPIRATORY TRACT INFECTION;

EID: 84896466973     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-1379.
2. Centers for Disease Control and Prevention. 2011 National Diabetes Fact Sheet. Available at: www.cdc.gov/diabetes/pubs/factsheet11.htm. Accessed June 10, 2013.
3. Food and Drug Administration. FDA approves Invokana to treat type-2 diabetes: frst in a new class of diabetes drugs. Available at: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345848.htm. Updated March 29, 2013. Accessed August 20, 2013.
4. American Diabetes Association. Standards of medical care in diabetes-2013: position statement. Diabetes Care 2013;36(Suppl 1):S11-66.
5. Aroda VR, Henry RR, Han J, et al. Effcacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther 2012;34:1247-1258.
6. Food and Drug Administration. FDA approved drug products. Available at: www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search. DrugDetails. Accessed May 29, 2013.
7. Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors. Drugs 2011;71(11):1441-1467.
8. Nesina (alogliptin), prescribing information. Deerfeld, IL: Takeda Pharmaceuticals America, Inc.; June 2013.
9. Andukuri R, Drincic A, Rendell M. Alogliptin: a new addition to the class of DPP-4 inhibitors. Diabetes Metab Syndr Obes 2009;2:117-126.
10. Golightly LK, Drayna CC, McDermott MT. Comparative clinical pharmacokinet-ics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet 2012;51(8):501-514.
11. Covington P, Christopher R, Davenport M, et al. Pharmacokinetic, pharmaco-dynamic, and tolerability profles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type-2 diabetes. Clin Ther 2008;30(3):499-512.
12. Karim A, Laurent A, Munsaka M, et al. Coadministration of pioglitazone or glyburide and alogliptin: pharmaco-kinetic drug interaction assessment in healthy participants. J Clin Pharmacol 2009;49:1210-1219.
13. Scott LJ. Alogliptin: a review of its use in the management of type-2 diabetes mel-litus. Drugs 2010;70:2051-2072.
14. Scheen AJ. Pharmacokinetics of dipepti-dyl peptidase-4 inhibitors. Diabetes Obes Metab 2010;12:648-658.
15. Karim A, Covington P, Christopher R, et al. Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects. Int J Clin Pharmacol Ther 2010;48:46-58.
16. DeFronzo RA, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type-2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care 2008;31:2315-2317.
17. Rosenstock J, Inzucchi SE, Seufert J, et al. Initial combination therapy with alo-gliptin and pioglitazone in drug-naïve patients with type-2 diabetes. Diabetes Care 2010;33:2406-2408.
18. th Annual Meeting of the European Association for the Study of Diabetes, Berlin, Germany, October 2012. Available at: www.abstractsonline.com/plan/ViewAbstract.aspx?mID=2978&sKey=590037db-1ab0-4abd-a68f-e98c3351797f&cKey=78e391c0-8d4a-4924-b6e8-f7d9fd2275dd&mKey=%7B2DBFCAF7-1539-42D5-8DDA-0A94ABB089E8%7D#. Accessed July 10, 2013.
19. Nauck MA, Ellis GC, Fleck PR, et al., for the Alogliptin Study 008 Group. Effcacy and safety of adding the dipeptidyl pepti-dase-4 inhibitor alogliptin to metformin therapy in patients with type-2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomized, double-blind, placebo-controlled study. Int J Clin Pract 2009;63:46-55.
20. Defronzo RA, Burant CF, Fleck P, et al. Effcacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type-2 diabetes. J Clin Endocrinol Metab 2012;97:1615-1622.
21. Pratley RE, Reusch JEB, Fleck PR, et al. Effcacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type-2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 2009;25:2361-2371.
22. Bosi E, Ellis GC, Wilson CA, Fleck PR. Alogliptin as a third oral antidiabetic drug in patients with type-2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. Diabetes Obes Metab 2011;13:1088-1096.
23. Pratley R, Kipnes M, Fleck P, et al., Alogliptin Study 007 Group. Effcacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type-2 diabetes inadequately controlled by gly-buride monotherapy. Diabetes Obes Metab 2009;11:167-176.
24. Rosenstock J, Rendell MS, Gross JL, et al. Alogliptin added to insulin therapy in patients with type-2 diabetes reduces HbA1c without causing weight gain or increased hypoglycemia. Diabetes Obes Metab 2009;11:1145-1152.
25. Rosenstock J, Wilson C, Fleck P. Alogliptin versus glipizide monotherapy in elderly type-2 diabetes mellitus patients with mild hyperglycemia: a prospective, double-blind, randomized, 1-year study. Diabetes Obes Metab 2013;doi:10.1111/ dom.12102.
26. Food and Drug Administration. FDA drug safety communication: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous fndings of the pancreas from incretin mimetic drugs for type-2 diabetes. Available at: www.fda.gov/Drugs/DrugSafety/ucm343187.htm. Updated March 18, 2013. Accessed February 9, 2014.
27. Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013;doi: 10.1111/dom.12176.
28. Food and Drug Administration, Center for Drug Evaluation and Research. Application number: 022271Orig1s000: Summary Review. Available at: www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000SumR.pdf. Accessed February 9, 2014.
29. Scott LJ. Alogliptin: a review of its use in the management of type-2 diabetes mel-litus. Drugs 2010;70:2051-2072.
30. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: diabetes mellitus-evaluat-ing cardiovascular risk in new antidia-betic therapies to treat type-2 diabetes. December 2008. Available at: http://www.fda.gov/downloads/Drugs/Guid-anceComplianceRegulatoryInformation/Guidances/UCM071627.pdf. Accessed February 9, 2014.
31. White WB, Pratley R, Fleck P, et al. Cardiovascular safety of the dipeptidyl peptidase-4 inhibitor alogliptin in type-2 diabetes mellitus. Diabetes Obes Metab 2013;15:668-673.
32. White WB, Bakris GL, Bergenstal RM, et al. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type-2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type-2 diabetes with acute coronary syndrome. Am Heart J 2011;162:620-626.
33. White WB, Canon C P, Heller SR. Alo-gliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-1335.
34. Fuji Y, Abe M, Higuchi T, et al. The dipep tidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Expert Opin Pharmacother 2013;14:259-267.
35. Red Book Online via Micromedex. Available at: www.micromedexsolutions.com. Accessed February 2, 2014.
36. Rendell M, Drincic A, Andukuri R. Alo-gliptin benzoate for the treatment of type-2 diabetes. Expert Opin Pharmacother 2012;13:553-563.
37. Neumiller JJ, Wood L, Campbell RK. Dipeptidyl peptidase-4 inhibitors for the treatment of type-2 diabetes mellitus. Pharmacotherapy 2010;30:463-484.
38. Tradjenta (linagliptin), prescribing information. Ridgefeld, CT: Boehringer Ingel-heim Pharmaceuticals, Inc.; June 2013.
39. Onglyza (saxagliptin), prescribing information. Princeton, NJ: Bristol-Myers Squibb Company. Accessed February 2, 2014.
40. Januvia (sitagliptin), prescribing information. Whitehouse Station, NJ: Merck & Co, Inc. Accessed February 2, 2014.
41. Micromedex Healthcare Series Website. Alogliptin. Available at: www.thomsonhc.com.ezproxy.samford.edu/home/dis-patch. Accessed July 27, 2013.